Dulaglutide vs Semaglutide
A neutral, side-by-side comparison of two glp-1 & metabolic peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Dulaglutide
Once-weekly GLP-1 receptor agonist (Trulicity) approved for type 2 diabetes and cardiovascular risk reduction. Engineered as a GLP-1 analogue fused to a modified IgG4-Fc domain, which provides a ~5-day half-life and enables once-weekly subcutaneous dosing via a simple auto-injector pen with no reconstitution required.
Full profileSemaglutide
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for type 2 diabetes management. It is FDA-approved under the brand names Ozempic (diabetes) and Wegovy (weight loss) and has become one of the most widely discussed peptides in mainstream health conversations.
Full profile| Dulaglutide | Semaglutide | |
|---|---|---|
| Category | GLP-1 & Metabolic | GLP-1 & Metabolic |
| Also known as | Trulicity, LY2189265 | Ozempic, Wegovy, Rybelsus, GLP-1 agonist |
| Evidence | FDA-approved | FDA-approved |
| Dosing range | 0.75mg–4.5mg mg, once weekly subcutaneous | 0.25mg–2.4mg mg, once weekly (injectable); once daily (oral Rybelsus) |
| Administration | Subcutaneous injection (auto-injector pen) | Subcutaneous injection (weekly — Ozempic/Wegovy), Oral tablet (daily — Rybelsus) |
| Key side effects | Nausea (most common), Diarrhea, Vomiting, Abdominal pain | Nausea (very common, especially during dose escalation), Vomiting, Diarrhea or constipation, Reduced appetite (intended effect) |
| Cited sources | 2 references | 4 references |
Key differences
- Administration: Dulaglutide — Subcutaneous injection (auto-injector pen); Semaglutide — Subcutaneous injection (weekly — Ozempic/Wegovy), Oral tablet (daily — Rybelsus).
- Frequency: Dulaglutide is typically once weekly subcutaneous; Semaglutide is once weekly (injectable); once daily (oral Rybelsus).
- Research depth: this profile cites 2 sources for Dulaglutide vs 4 for Semaglutide.
How each works
Dulaglutide
Dulaglutide's large molecular structure (fusion with IgG4-Fc) prevents renal filtration and extends half-life via FcRn recycling, enabling once-weekly dosing. The REWIND cardiovascular outcomes trial demonstrated significant reduction in major adverse cardiovascular events (MACE) in patients with or at risk for cardiovascular disease, establishing dulaglutide as a cardioprotective agent beyond glucose control.
Semaglutide
Semaglutide has robust clinical trial data — including the STEP and SUSTAIN trial series — demonstrating significant weight loss (15–20% body weight), glycemic control, and cardiovascular risk reduction. It works by mimicking the GLP-1 hormone, slowing gastric emptying, increasing insulin secretion, and reducing appetite via central nervous system signaling.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.